Clinical Trials Browser

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00389701 2014-01-10

Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

Phase 2 Unknown

30 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00742404 2013-12-18

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Unknown

35 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00317811 2013-11-06

Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

35 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00243035 2013-10-08

Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

Phase 1/2 Terminated

64 enrolled

Plasma cell

Multiple Myeloma

NCT00316940 2013-09-20

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

36 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00303797 2013-03-19

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

Phase 1 Completed

50 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00310024 2013-02-07

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

40 enrolled

Plasma cell

Multiple Myeloma

NCT00438841 2009-03-13

Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma

Phase 2 Unknown

43 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell